Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amiksin
- Development stage
- Phase 1
- Lead developer
- OTCPharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amiksin is an orally administered antiviral and immunomodulatory small molecule drug developed and marketed by OTCPharm in Russia. Its active ingredient is tilorone dihydrochloride, which functions as a low-molecular-weight synthetic interferon inducer. The drug stimulates the endogenous production of alpha, beta, and gamma interferons in various cell types, including intestinal epithelial cells, hepatocytes, T-lymphocytes, and neutrophils. Its antiviral mechanism of action involves the inhibition of virus-specific protein translation in infected cells, which effectively suppresses viral replication. Amiksin is approved for the treatment and prevention of several viral conditions, including influenza, acute respiratory viral infections (ARVI), viral hepatitis A, B, and C, herpes simplex, and cytomegalovirus infections. Additionally, it is used as part of complex therapy for infectious-allergic and viral encephalomyelitis, as well as urogenital and respiratory chlamydia.
- Brand names
- AmiksinAmixin
- Other names
- tiloronetilorone dihydrochloride
02
Targets
AcetylcholinesteraseCHRNA7 (α7 nicotinic receptor)IFN-α (Interferon alpha-7)IFN-β (Interferon beta)IFNG (Interferon gamma)
Beyond the preview
Go deeper on Amiksin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amiksin.